In some chronic myeloid leukemia (CML) and AML, especially with high PTGDR2 expression in FAB subtypes M2, M3, and M6, patients showed better survival, suggesting that high PTGDR2 expression might be a target for leukemia therapy [51]. The gene discussed is PTGDR2; the disease is acute myeloid leukemia.